The overall cystic fibrosis market is expected to surge due to the increasing prevalence of the disease and expected launch of emerging therapies including Ensifentrine, VX-121/TEZ/ VX561, and others in the forecasted period (2022-2032).
LAS VEGAS, Oct. 12, 2022 /PRNewswire/ -- DelveInsight's Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
Key Takeaways from the Cystic Fibrosis Market Report
- As per DelveInsight analysis, the cystic fibrosis market size in the 7MM was approximately USD 7.1 billion in 2021.
- According to the assessment done by DelveInsight, the estimated total cystic fibrosis diagnosed prevalent cases in the 7MM were approximately 65.5K in 2021.
- Globally, leading cystic fibrosis companies such as Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc., Krystal Biotech, Translate Bio, Novartis, Algi Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Galapagos NV, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others are developing new cystic fibrosis drugs that can be available in the cystic fibrosis market in the coming years.
- The promising cystic fibrosis therapies in the pipeline include Ensifentrine, ELX-02, VX-121/TEZ/ VX-561, POL6014 (Lonodelestat), LAU-7b, and others.
- The increase in cystic fibrosis market size is a direct consequence of the expected launch of potential therapies, along with increasing awareness and development of novel therapies.
Discover which therapies are expected to grab the major cystic fibrosis market share @Cystic Fibrosis Market Report
Cystic Fibrosis Overview
Cystic fibrosis is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. F508del is the most common variation reported globally, but there are over 2000 others, not all causing the disease.
The cystic fibrosis symptoms usually appear 6-8 months after birth, though this varies significantly from person to person. Cystic fibrosis symptoms vary with age and can affect different body parts. Newborn screening, a genetic test to look for a gene defect, and a blood test to look for pancreatic problems are two tests used for cystic fibrosis diagnosis. After initial testing, a sweat test can be performed to confirm the cystic fibrosis diagnosis.
Cystic Fibrosis Epidemiology Segmentation
DelveInsight estimates that there were approximately 65.5Kdiagnosed prevalent cases of cystic fibrosis in the 7MM in 2021.
Among the EU5 countries, the UK had the highest number of cystic fibrosis diagnosed prevalent cases in 2021.
The cystic fibrosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Diagnosed Prevalent Cases of Cystic Fibrosis
- Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis
- Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis
- Mutation-specific Diagnosed Prevalent Cases of Cystic Fibrosis
Download the report to understand which factors are driving cystic fibrosis epidemiology trends @Cystic Fibrosis Epidemiological Insights
Cystic Fibrosis Treatment Market
Current cystic fibrosis medications focus on symptom relief, complication prevention, and, more recently, protein rectifiers to correct underlying structural and functional abnormalities. Inhaled antibiotics are used to treat chronic lung infections, mucolytics are used to reduce the viscosity of pulmonary mucus, pancreatic enzyme replacement therapy (PERT) is used to treat CF-associated exocrine pancreatic insufficiency (PPI), and CFTR modulators are used to improve CFTR function while addressing the underlying cause of the disease.
In addition to mucolytics like dornase alfa, hypertonic saline inhalation has been proposed as a therapy for increasing the hydration of airway surface liquid in cystic fibrosis patients. Pancreatic enzyme supplements, multivitamins (particularly fat-soluble vitamins), mucolytics, antibiotics (including inhaled, oral, or parenteral), bronchodilators, anti-inflammatory agents, and CFTR potentiators (e.g., ivacaftor) and correctors (e.g., elexacaftor, lumacaftor,tezacaftor) may be used to treat patients with cystic fibrosis.
The current cystic fibrosis treatment is primarily based on CFTR modulators and supportive therapies such as mucolytics, antibiotics, bronchodilators, and others. TRIKAFTA, SYMDEKO, ORKAMBI, and KALYDECO currently dominate the cystic fibrosis market.
Generally, a normal diet with additional energy and unrestricted fat intake is advised. To compensate for malabsorption and the increased energy demand of chronic inflammation, a high-energy and high-fat diet is recommended, along with supplemental vitamins (especially fat-soluble) and minerals. Sometimes cystic fibrosis causes issues that can only be resolved through surgery or another type of medical procedure.
To know more about cystic fibrosis medications, visit @Cystic Fibrosis Treatment Market
Cystic Fibrosis Pipeline Therapies and Key Companies
- Ensifentrine: Verona Pharmaceuticals
- ELX-02: Eloxx Pharmaceuticals, Inc.
- VX-121/TEZ/ VX-561: Vertex Pharmaceuticals
- POL6014 (Lonodelestat): Santhera Pharmaceuticals
- LAU-7b: Laurent Pharmaceuticals Inc.
Learn more about the FDA-approved drugs for cystic fibrosis treatment @Cystic Fibrosis Drugs
Cystic Fibrosis Market Dynamics
The overall prevalence of cystic fibrosis is expected to rise over the forecast period, creating new opportunities for pharma players in the cystic fibrosis market. Moreover, existing therapies have room for label expansions to improve efficacy, propelling the cystic fibrosis market forward.
Furthermore, there are lucrative opportunities to address unmet therapeutic needs in the cystic fibrosis market regarding tolerability, drug resistance, dosage, and adverse effects. More combinational drugs with higher efficacy are needed.
With advancements in diagnostic tools and palliative care, the median cystic fibrosis life expectancy in the United States has risen from a few months to 46 years. Several cystic fibrosis drugs are currently being used to treat cystic fibrosis, with evidence ranging from randomized, double-blind, placebo-controlled clinical trials to anecdotal case reports. Many more are currently in the works. Pharma companies have been proactive in their research in the cystic fibrosis market, recognizing that the treatment has a long way to go.
However, due to the lack of significant competitors, the current cystic fibrosis market players will likely maintain their competitive positions throughout the study period. Despite improved outcomes, most cystic fibrosis patients die from pulmonary complications, making this one of the most significant underlying challenges in the cystic fibrosis treatment paradigm.
Moreover, the patient's pharmacological treatment history is complicated, with a plethora of drugs resulting in resistance and a constant shift in treatment regimens. Any generic drug entry will impede the cystic fibrosis market for branded drugs. Even Vertex has plans for generic cystic fibrosis medications.
Report Metrics | Details |
Study Period | 2019-2032 |
Coverage | 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] |
Base Year | 2021 |
Market CAGR | 9 % |
Market Size in 2021 | USD 7.1 Billion |
Key Cystic Fibrosis Companies | Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc., Krystal Biotech, Translate Bio, Novartis, Algi Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Galapagos NV, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others |
KeyCystic Fibrosis Therapies | Ensifentrine, ELX-02, VX-121/TEZ/ VX-561, POL6014 (Lonodelestat), LAU-7b, and others |
Scope of the Cystic Fibrosis Market Report
- Therapeutic Assessment: Cystic Fibrosis current marketed and emerging therapies
- Cystic FibrosisMarket Dynamics: Cystic Fibrosis market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Cystic Fibrosis Market Access and Reimbursement
Discover more about drugs for cystic fibrosis in development @Cystic Fibrosis Clinical Trials
Table of Contents
1. | Cystic Fibrosis Market Key Insights |
2. | Cystic Fibrosis Market Report Introduction |
3. | Cystic Fibrosis Market Overview at a Glance |
4. | Cystic Fibrosis Market Executive Summary |
5. | Disease Background and Overview |
6. | Cystic Fibrosis Treatment and Management |
7. | Cystic Fibrosis Epidemiology and Patient Population |
8. | Patient Journey |
9. | Cystic Fibrosis Marketed Drugs |
10. | Cystic Fibrosis Emerging Drugs |
11. | Seven Major Cystic Fibrosis Market Analysis |
12. | Cystic Fibrosis Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Cystic Fibrosis Market Drivers |
16. | Cystic Fibrosis Market Barriers |
17. | Unmet Needs |
18. | SWOT Analysis |
19. | Appendix |
20. | DelveInsight Capabilities |
21. | Disclaimer |
22. | About DelveInsight |
Related Reports
Cystic Fibrosis Epidemiology Forecast
Cystic Fibrosis Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the cystic fibrosis epidemiology trends.
Cystic Fibrosis Pipeline
Cystic Fibrosis Pipeline Insight - 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key cystic fibrosis companies, including Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, among others.
Non-Cystic Fibrosis Bronchiectasis Market
Non-Cystic Fibrosis Bronchiectasis Market Insight, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key non-cystic fibrosis bronchiectasis companies, including AstraZeneca, Insmed, Novartis, CSL Behring, Arrowhead Pharmaceuticals, among others.
Non-Cystic Fibrosis Bronchiectasis Pipeline
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight - 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key non-cystic fibrosis bronchiectasis companies, including AstraZeneca, Insmed, Novartis, CSL Behring, Arrowhead Pharmaceuticals, among others.
Non-Cystic Fibrosis Bronchiectasis Epidemiology
Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the non-cystic fibrosis bronchiectasis epidemiology trends.
Airway Clearance Devices for Cystic Fibrosis Market
Airway Clearance Devices for Cystic Fibrosis Market Insight, Competitive Landscape, and Market Forecast - 2027 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key airway clearance devices for cystic fibrosis companies, including Dymedso, PARI GmBH, Thayer Medical, Electromed, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market
Related Healthcare Blogs
Cystic Fibrosis Market
Increasing COPD Prevalence
ARDS Market Outlook
Emerging ARDS Therapies
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cystic-fibrosis-market-to-showcase-growth-at-a-cagr-of-9-during-the-forecast-period-20222032--delveinsight-301646922.html
